Welcome to our dedicated page for Fulgent Genetics news (Ticker: FLGT), a resource for investors and traders seeking the latest updates and insights on Fulgent Genetics stock.
Fulgent Genetics, Inc. (NASDAQ: FLGT) regularly issues news and updates that reflect its dual focus on laboratory services and oncology therapeutic development. Company press releases cover topics such as quarterly and annual financial results, clinical trial progress for its cancer drug candidates, regulatory milestones for its genomic testing platforms, and strategic transactions in the laboratory and pathology space. Because Fulgent describes itself as a technology-based company with ambitions in precision medicine, its news flow often highlights both operational performance and advances in its technology and therapeutic pipelines.
Investors following FLGT news can expect detailed earnings releases that discuss revenue, core revenue, GAAP and non-GAAP results, gross margins, and adjusted EBITDA, along with commentary from management on business trends in the laboratory services and therapeutic development segments. The company also announces the timing of upcoming earnings calls and investor conference presentations through news releases, providing context for when management will discuss the business with the investment community.
Beyond financial reporting, Fulgent’s news includes updates on its oncology programs, such as preliminary clinical data from trials of FID-007 in recurrent or metastatic head and neck squamous cell carcinoma. The company also reports on regulatory achievements, including CE certification in the European Union for its FulgentExome and Fulgent Pipeline Manager (PLM) germline next-generation sequencing system. In addition, Fulgent uses press releases to announce strategic moves in laboratory and pathology services, such as its agreement to acquire selected assets of Bako Diagnostics and to acquire StrataDx.
This FLGT news page aggregates these types of announcements so readers can review financial disclosures, clinical development updates, technology milestones, and transaction-related news in one place. For those tracking Fulgent’s progress toward its stated goal of becoming a fully integrated precision medicine company, the news feed provides an ongoing view of how the company reports its operational and strategic developments.
Fulgent Genetics (NASDAQ: FLGT), a technology-based company operating in laboratory services and therapeutic development, has scheduled its first quarter 2025 financial results announcement for Friday, May 2, 2025, before market opening.
The company will host an investment community conference call at 8:30 AM ET (5:30 AM PT) on the same day. Management will present the results and conduct a Q&A session. Investors can access the live audio webcast through the Investor Relations section of Fulgent's website, with an audio replay available afterward.
Fulgent Genetics (NASDAQ: FLGT) has reported its financial results for Q4 and full year 2024. The company achieved total revenue of $283.5 million for the full year, with core revenue growing 7% year-over-year to $281.2 million.
Key financial highlights include:
- Q4 total revenue of $76.2 million with core revenue up 14% year-over-year to $76.0 million
- Full year GAAP loss of $42.7 million, or ($1.41) per share
- Non-GAAP income of $15.0 million, or $0.49 per share
- Strong cash position of $828.6 million ($26.87 per share)
For 2025, Fulgent projects core revenue of approximately $310 million, with an expected GAAP loss of ($1.95) per share and non-GAAP loss of ($0.65) per share. The company anticipates ending 2025 with approximately $780 million in cash and investments.
Fulgent Genetics (NASDAQ: FLGT) has announced it will release its fourth quarter and full year 2024 financial results before market opens on Friday, February 28, 2025. The company will host a conference call for investors at 8:30 AM ET (5:30 AM PT) on the same day, where management will discuss results and answer questions. The call will be accessible through a live audio webcast on the Investor Relations section of Fulgent's website, with an audio replay available afterward.
Foundation Medicine announced plans to launch two new germline tests in the United States through a partnership with Fulgent Genetics (NASDAQ: FLGT). The tests, FoundationOne®Germline and FoundationOne®Germline More, will be available from February 28, 2025, and can be added to any Foundation Medicine comprehensive genomic profiling test.
FoundationOne®Germline analyzes 50 genes associated with hereditary cancers, while FoundationOne®Germline More is an expanded panel analyzing 154 genes. Both tests use Fulgent's proprietary technology platform to analyze single nucleotide and copy number variations. When combined with Foundation Medicine's existing tests, they help healthcare providers build comprehensive molecular profiles for cancer patients, explaining cancer development and potential future cancer risks.
Fulgent Genetics (NASDAQ: FLGT) reported Q3 2024 financial results with total revenue of $71.7 million, representing a 9% year-over-year growth in core revenue. The company posted a GAAP loss of $14.6 million (-$0.48 per share) and non-GAAP income of $9.4 million ($0.31 per share). The company maintains strong liquidity with $815.4 million in cash and investments.
Fulgent reiterates its full-year 2024 core revenue guidance of $280 million and improves its GAAP loss guidance from -$1.95 to -$1.70 per share. The company also revised its non-GAAP outlook from a loss of $0.30 per share to an income of $0.33 per share.
Fulgent Genetics (NASDAQ:FLGT) has announced its management team's upcoming participation in two major healthcare conferences. The company will present at the UBS Global Healthcare Conference on November 12th at 2:45 PM Pacific Time and the Piper Sandler 36th Annual Healthcare Conference on December 4th at 11:30 AM Eastern Time.
Live webcasts of both presentations will be available on Fulgent's Investor Relations website, with replay options accessible approximately one hour after each event concludes.
Fulgent Genetics (NASDAQ: FLGT) has secured a five-year contract worth up to $99M from the U.S. Department of Veterans Affairs to provide hereditary cancer and pharmacogenetic testing to Veterans. The company, which has been offering genetic testing services to VA members since 2017, will expand its services to include hereditary cancer tests for individuals with cancer or family history of certain cancers. The contract also covers pharmacogenetic testing, which uses genomic information to determine medication responses. Fulgent's comprehensive suite of germline tests enables custom solutions, utilizing next-generation sequencing for higher resolution and greater coverage.
Fulgent Genetics (NASDAQ: FLGT) has announced it will release its third quarter 2024 financial results before the market opens on Friday, November 8, 2024. The company, which operates a laboratory services business and a therapeutic development business, will host a conference call for investors at 8:30 AM ET (5:30 AM PT) on the same day.
Management will discuss the results and answer questions during the call. Investors can access the live audio webcast through the Investor Relations section of Fulgent's website at http://ir.fulgentgenetics.com. An audio replay will also be available at the same location following the call.
Fulgent Genetics (NASDAQ: FLGT) reported Q2 2024 financial results with total revenue of $71.0 million. Core Revenue grew 5% year-over-year to $70.2 million. The company reported a GAAP loss of $8.7 million, or ($0.29) per share, and Non-GAAP income of $4.7 million, or $0.15 per share. Fulgent reiterated its Full Year 2024 Core Revenue Guidance of $280 million and improved its Earnings Per Share Guidance. The company maintains a strong cash position with $837.9 million in cash, cash equivalents, and investments as of June 30, 2024. Fulgent's Laboratory Services continue to show strength, particularly in Precision Diagnostics, while its Therapeutics Development segment progresses with clinical trials.